Browse the evidence

Among pharmacotherapies, Semaglutide 2.4 mg and Orlistat have the most favorable safety/tolerability profiles, while Liraglutide 3.0 mg has the least tolerability, and Tirzepatide has intermediate tolerability.

When choosing a weight loss medication, be aware that tolerability varies. Semaglutide and Orlistat tend to be better tolerated, while Liraglutide may cause more side effects. Tirzepatide, despite its high efficacy, has intermediate tolerability, meaning you might experience more side effects than with Semaglutide or Orlistat.

Meal replacements improve satiety and reduce cravings during caloric restriction through mechanisms like stimulus narrowing and ketosis, despite expected hormonal changes.

You might worry that eating less will make you hungry, but using meal replacements can actually help control hunger. By limiting food choices (stimulus narrowing) and potentially inducing ketosis, MRs can reduce cravings and make sticking to a diet easier.

Continued treatment with Tirzepatide maintains significant weight loss and cardiometabolic improvements, whereas discontinuation leads to partial weight regain and loss of benefits, demonstrating that long-term adherence is required to sustain outcomes.

If you are using Tirzepatide for weight loss, understand that it is a long-term treatment, not a short-term fix. Stopping the medication will likely cause you to regain most of the weight you lost. To keep the weight off, you must continue the medication indefinitely, combined with healthy lifestyle habits, just as you would manage high blood pressure with medication.

A higher triglyceride-glucose (TyG) index, serving as a surrogate marker for insulin resistance, is significantly associated with increased risks of composite cardiovascular events, cardiovascular mortality, myocardial infarction, stroke, and incident type 2 diabetes.

Your risk for heart disease and diabetes is closely linked to your insulin resistance, which can be estimated using a simple calculation from your fasting triglyceride and glucose levels. This risk is not uniform; it is significantly higher for people living in low- and middle-income countries. Regular monitoring of these markers can help identify those at high risk for cardiovascular events and diabetes, allowing for earlier intervention.

Resistance exercise-induced skeletal muscle hypertrophy is primarily regulated by internal biological variables (e.g., mechanotransduction, mTORC1 signaling, ribosomal biogenesis) rather than external programming alone, with internal variables acting as the dominant determinant of the hypertrophic response.

To maximize muscle growth, focus on consistent resistance training that provides mechanical load. Your body's internal biological machinery (signaling pathways, gene expression) will determine how much muscle you build from that load. Don't chase acute hormone spikes or muscle soreness, as these are not the primary drivers of long-term hypertrophy.

AOM therapy requires monitoring and potential dose reduction of concomitant medications for diabetes and hypertension due to rapid weight loss and improved metabolic parameters.

If you take medication for diabetes or high blood pressure, tell your doctor you are starting an AOM. Your doses may need to be lowered quickly as you lose weight to prevent dangerous drops in blood sugar or blood pressure.

Metformin is the primary first-line oral treatment for type 2 diabetes across all age groups due to its efficacy, versatility, and cost-effectiveness, with benefits extending to cardiovascular and potential anti-neoplastic properties.

Start with metformin as your primary medication. It is the standard, effective, and affordable choice for managing blood sugar. While it may cause mild stomach issues initially, it is generally well-tolerated and helps protect your heart and kidneys over the long term.

GLP-1 receptor agonists improve cardiovascular risk factors (blood pressure, lipid profiles, endothelial function) and reduce cardiovascular events in patients with type 2 diabetes and obesity.

GLP-1 injections not only help with weight and blood sugar but also improve heart health by lowering blood pressure, improving cholesterol, and reducing inflammation. They are recommended for patients with T2DM and obesity to reduce cardiovascular risk.

Statins are safe and effective as first-line treatment for hyperlipidemia in MASLD patients, despite under-prescription, and may reduce cardiovascular events and liver disease burden.

If you have MASLD and high cholesterol or CVD risk, ask your doctor about statins. They are safe for your liver, even if you have some liver scarring, and are the first-line treatment to lower your risk of heart disease. Do not avoid them due to fear of liver damage.

Tirzepatide treatment significantly reduces the 10-year predicted risk of atherosclerotic cardiovascular disease (ASCVD) in adults with obesity or overweight without diabetes compared to placebo.

If you have obesity or overweight without diabetes, treatment with tirzepatide (a once-weekly injection) combined with lifestyle changes can significantly lower your calculated 10-year risk of heart disease compared to placebo. This benefit was observed across different baseline risk levels, suggesting it may be a valuable option for long-term cardiovascular health improvement in this population.

SGLT-2 inhibitors reduce body weight (0.9-2.5 kg) and improve cardiovascular and renal outcomes in patients with diabesity by inducing glycosuria, making them a valuable class of medication for managing both metabolic and organ-specific risks.

SGLT-2 inhibitors (like Jardiance or Farxiga) are oral diabetes medications that also help with modest weight loss (1-2.5 kg) and protect your heart and kidneys. They work by removing excess sugar through urine. While this can increase the risk of yeast infections or UTIs, good hygiene and doctor guidance can manage this. They are particularly beneficial if you have heart or kidney risks associated with your diabetes.

The hypertrophic benefit of creatine supplementation is modestly greater in younger adults compared to older adults, although the effect remains small in both groups.

Younger lifters may see a slightly better muscle growth boost from creatine than older lifters, but the difference is small. Older adults should still use creatine as it provides a small benefit, even if the magnitude is lower than in youth.

GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide) provide a net health benefit for weight loss in non-diabetic adults with obesity, but only when the treatment goal is achieving ≥10% body weight loss; achieving 5% weight loss results in a net harm due to side effects.

If you are considering GLP-1 medications for weight loss without diabetes, understand that these drugs are most effective and 'worth it' if you aim to lose 10% or more of your body weight. Losing only 5% may actually result in a net negative health outcome due to side effects like nausea and vomiting. Ensure you are committed to lifestyle changes (diet and exercise) alongside the medication, and discuss your specific weight loss goals and tolerance for side effects with your doctor.

Intensive glucose-lowering strategies in type 2 diabetes significantly reduce the risk of non-fatal myocardial infarction and microvascular complications (retinopathy, nephropathy) compared to standard therapy, but do not significantly reduce major adverse cardiovascular events (MACE) or all-cause mortality.

For people with Type 2 Diabetes, aiming for very low blood sugar levels (intensive control) is beneficial for protecting your eyes and kidneys, and may slightly reduce the risk of non-fatal heart attacks. However, it does not significantly reduce the risk of major heart events, stroke, or death compared to standard control. Therefore, intensive glucose lowering should be combined with aggressive management of blood pressure and lipids, rather than being the sole focus for heart health.

GLP-1 receptor agonists (GLP-1RAs) significantly improve liver enzymes (AST, ALT, GGT) and reduce fibrosis scores in patients with MAFLD and T2DM, though they are not recommended as a primary treatment for NASH histology in the absence of diabetes.

If you have type 2 diabetes and fatty liver, GLP-1 medications (like Semaglutide) can significantly improve your liver enzymes and reduce scarring markers. They are recommended by guidelines for this specific group. However, they can cause stomach issues like nausea, which leads many people to stop taking them. Discuss with your doctor if the benefits for your liver and heart outweigh the side effects.

Daily supplementation with a combination of nicotinamide riboside (NR) and pterostilbene (NRPT) at the recommended dose significantly reduces circulating levels of hepatic inflammation markers (ALT and GGT) and toxic lipids (ceramide 14:0) in adults with Non-Alcoholic Fatty Liver Disease (NAFLD) over 6 months, without reducing hepatic fat fraction.

If you have NAFLD, a specific combination of Nicotinamide Riboside and Pterostilbene (taken daily at the recommended dose) may help lower liver inflammation markers (ALT, GGT) and toxic lipids over 6 months. However, do not expect this supplement to reduce the actual amount of fat in your liver, as the study showed no improvement in hepatic fat fraction compared to a placebo.

Semaglutide administration significantly reduces the incidence of atrial fibrillation by 42% compared to placebo in patients at high cardiovascular risk, primarily those with type 2 diabetes or obesity.

If you have type 2 diabetes or are overweight with high heart disease risk, ask your doctor about semaglutide. This medication has been shown to significantly lower your chance of developing atrial fibrillation, a common heart rhythm problem, regardless of whether you take it as a pill or a weekly injection. This benefit exists even if you do not have diabetes.

GLP-1 receptor agonists (Liraglutide, Semaglutide, Tirzepatide) are effective for chronic weight management in obese patients, but improper use without clinical indication can lead to serious side effects.

GLP-1 drugs like Semaglutide and Tirzepatide are effective for weight loss in obese patients with comorbidities. However, they are prescription medications with serious side effects. Do not use them without medical indication or supervision. Follow your doctor's dosage and monitoring plan.

Tirzepatide treatment (5-15 mg once weekly) significantly improves health-related quality of life (HRQoL), including physical function and psychosocial well-being, compared to placebo in adults with obesity or overweight.

If you have obesity or overweight, treatment with tirzepatide (5-15 mg once weekly) along with lifestyle changes significantly improves your quality of life, physical function, and mental well-being compared to placebo. The greater the weight loss achieved (especially ≥5%), the greater the improvement in how you feel and function daily.

Caloric restriction triggers adaptive thermogenesis, including reduced BMR/RMR, hormonal shifts (lowered T3, leptin, increased ghrelin), and increased appetite, which persist long-term and contribute to weight regain.

When you restrict calories, your body fights back by lowering your metabolic rate and increasing hunger hormones. This is a survival mechanism, not a personal failing. To manage this, consider strategies that preserve muscle mass, manage stress, and perhaps use precision nutrition to mitigate these adaptive responses.

Cotadutide, a dual GLP-1 and glucagon receptor agonist, significantly reduces urinary albumin-to-creatinine ratio (UACR) in patients with type 2 diabetes and chronic kidney disease compared to placebo, with effects sustained over 26 weeks.

If you have type 2 diabetes and early kidney disease, cotadutide (a daily injection) significantly reduces albumin in your urine, a key marker of kidney health. This effect is seen at higher doses (300-600 mg) and is sustained over time. It works on top of your current medications. While it causes some GI side effects, these are generally manageable and similar to other GLP-1 drugs. Discuss with your doctor if this dual-agonist approach is right for you, especially if you are not getting enough kidney protection from current treatments.

Obesity is an independent risk factor for the onset and progression of chronic kidney disease (CKD), with visceral adiposity and fatty kidney disease serving as key pathophysiological mediators.

Maintaining a healthy weight is critical for kidney health. Excess visceral fat directly harms kidney function through inflammation and blood pressure changes. Weight management is a primary strategy to prevent or slow kidney disease.

GLP-1 receptor agonists (e.g., semaglutide) induce significant weight loss and reduce albuminuria, offering potential kidney protection, though their direct impact on eGFR decline in normal-functioning kidneys is not yet fully established.

GLP-1 medications like semaglutide help with weight loss and have been shown to reduce albuminuria (a sign of kidney stress). They are a promising option for kidney protection, especially for those with diabetes and obesity.

GLP-1 receptor agonists (specifically semaglutide and liraglutide) improve liver histology in MASH patients, with semaglutide demonstrating the strongest evidence for resolving steatohepatitis without worsening fibrosis.

If you have MASH, GLP-1 medications like semaglutide are currently the most evidence-backed pharmacological option to improve liver health, potentially resolving the disease without worsening scarring. This is particularly relevant if you also have Type 2 Diabetes or obesity, as these drugs address the underlying metabolic drivers. While weight loss contributes, the histological benefits appear to extend beyond weight reduction alone.